Efficacy and tolerability of naltrexone in the management of alcohol dependence.
about
Improving clinical outcomes for naltrexone as a management of problem alcohol useThe efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models.Difference of the naltrexone's effects in social drinkers by spicy food preference.Risk factors and outcomes associated with alcohol relapse after liver transplantationSeparate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant usersThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence.Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5.Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J MicePsychostimulant addiction treatment.Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic systemChronic ethanol increases systemic TLR3 agonist-induced neuroinflammation and neurodegenerationCritical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.Adoption of medications in substance abuse treatment: priorities and strategies of single state authoritiesSeparate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.Management of alcohol dependence in patients with liver disease.Naltrexone extended-release injection: an option for the management of opioid abuse.Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.Pharmacotherapy of alcoholic liver disease in clinical practice.New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders.Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.The effectiveness of continuing group psychotherapy for outpatients with alcohol dependence: 77-month outcomes.Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.Evaluation in alcohol use disorders - insights from the nalmefene experiencePharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist.Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics forIncreased ethanol intake in prodynorphin knockout mice is associated to changes in opioid receptor function and dopamine transmission.Mixed learning algorithms and features ensemble in hepatotoxicity prediction.Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study.Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.Medications for alcohol use disorders: An overview.Pharmacotherapy for adolescent alcohol use disorder.Outpatient Detoxification Completion and One-Month Outcomes for Opioid Dependence: A Preliminary Study of a Neuropsychoanalytic Treatment in Pain Patients and Addicted PatientsAccess to care for people with alcohol use disorder in France: a mixed-method cross-sectional study protocol (ASIA)
P2860
Q27021406-0862D59E-256F-4459-9213-D33DE480FCE3Q30408902-74A96025-ED32-410D-B1DA-E53480EC2950Q33627503-BF776F3F-DCDB-4176-973B-CB707FB565D6Q33810165-BFC55B36-7D4F-4C7B-B751-3A106200E126Q33817870-4C5C75BB-E577-4E72-871E-617A95C3C328Q33870389-04A6D5FE-4331-4160-8707-3BBBECD454B9Q34306652-AA42F27B-0FD4-40E6-959C-F0B5646F4B08Q35128787-B0E79869-8D30-4C88-B6E6-F751D1087AAEQ35220086-235EBCA7-5B7D-4567-9C81-B83E2346EFB4Q35490468-C0F3E84E-0A1A-4419-A589-175674706E33Q35889376-FB365957-8DF0-4997-A878-D1A6C8BBD52AQ35915231-324E9D99-4B7C-4F8E-9E65-D5C8D6FB6514Q35995415-25DAA575-3234-4AF7-9520-D74A33009E86Q36143485-B5082DFB-22D6-4D1E-B025-D9110C857207Q36372867-53CFB746-AD80-48DF-9A5A-66EF7D6880CBQ36806539-559FA931-E959-41EF-8776-26767B9050F7Q36813937-CB28ADAA-8744-4563-87EC-FF31100BDF5FQ37165425-7C851564-0B35-4156-90C3-2AE838D96278Q37355293-4852F5EE-06EF-4A59-8901-CBF3087AF062Q38207128-DDF1058F-D126-4EE2-9859-485072EEA3B8Q38373652-C8A3C494-28F4-45B2-B2EF-090E7EFEF2DDQ38681092-61B87D50-E6C1-4FA7-B616-D029B7DE1854Q38843745-38CB5B62-3042-42EB-90AC-49AE74DDA117Q39144955-E97971A1-312B-481E-BAF7-4C3787941080Q39703732-47826197-EA35-4606-8C16-A13516640533Q41477480-167D768A-DCB1-4883-B3FA-A2D4B87352E1Q42348636-DF2AB9EB-2FD4-4799-A946-2519DAF8AE76Q42370953-A7DBA7B7-11CC-4CE5-949F-FC64E6819CFEQ42633385-57F4CC5A-9047-4FC5-B799-C3330171BB7FQ44330916-F76705E2-A072-494B-81D9-F82ADB7DA18EQ45372748-38B3C5E3-1093-45DD-9877-99364EC017FAQ47096944-64EFEA39-9AF9-4E89-BC83-769BB2F26A2CQ47698059-6A75A131-D457-468B-8E5F-CDE5517C544EQ47936236-7295D4C9-6230-4ACB-ADF7-4058FAEE7FB9Q47942161-3A4E5A8E-A7F5-42C8-889A-E78AA400D47CQ47984054-59272F02-1349-4446-BF40-A37D5102E3B1Q57399783-4A177822-B54C-4F2D-B3D9-803956D09472Q59125688-94925D85-EE8D-4467-892D-C71795FA900B
P2860
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@ast
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@en
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@nl
type
label
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@ast
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@en
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@nl
prefLabel
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@ast
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@en
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@nl
P1476
Efficacy and tolerability of naltrexone in the management of alcohol dependence.
@en
P304
P356
10.2174/138161210791516459
P4011
da6673d6f87f9969d8e7b5e86cba33e3beb34601
P577
2010-01-01T00:00:00Z